204 related articles for article (PubMed ID: 27816971)
21. Requirements for control of B-cell lymphoma by NK cells.
Brenner CD; King S; Przewoznik M; Wolters I; Adam C; Bornkamm GW; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2010 Feb; 40(2):494-504. PubMed ID: 19950185
[TBL] [Abstract][Full Text] [Related]
22. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
23. IFN-gamma production and degranulation are differentially regulated in response to stimulation in murine natural killer cells.
Vahlne G; Becker S; Brodin P; Johansson MH
Scand J Immunol; 2008 Jan; 67(1):1-11. PubMed ID: 18028287
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
25. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A; Taghi Khani A; Duault C; Aramburo S; Sanchez Ortiz A; Lee SJ; Chan A; McDonald T; Huang M; Lacayo NJ; Sakamoto KM; Yu J; Hurtz C; Carroll M; Tasian SK; Ghoda L; Marcucci G; Gu Z; Rosen ST; Armenian S; Izraeli S; Chen CW; Caligiuri MA; Forman SJ; Maecker HT; Swaminathan S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217248
[TBL] [Abstract][Full Text] [Related]
26. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
27. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
Tietje A; Li J; Yu X; Wei Y
Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
[TBL] [Abstract][Full Text] [Related]
28. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
[TBL] [Abstract][Full Text] [Related]
29. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
30. Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer.
Langers I; Renoux V; Reschner A; Touzé A; Coursaget P; Boniver J; Koch J; Delvenne P; Jacobs N
Eur J Immunol; 2014 Dec; 44(12):3585-95. PubMed ID: 25229656
[TBL] [Abstract][Full Text] [Related]
31. Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.
Boukouaci W; Al-Daccak R; Dulphy N; Lauden L; Amokrane K; Fortier C; Marzais F; Bennabi M; Peffault de Latour R; Socie G; Toubert A; Charron D; Krishnamoorthy R; Tamouza R
Hum Immunol; 2013 Dec; 74(12):1536-41. PubMed ID: 23994587
[TBL] [Abstract][Full Text] [Related]
32. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
33. Natural Killer Cell Activating Receptor NKG2D Is Involved in the Immunosuppressive Effects of Mycophenolate Mofetil and Hepatitis B Virus Infection.
Dong S; Geng L; Shen MD; Zheng SS
Am J Med Sci; 2015 May; 349(5):432-7. PubMed ID: 25828197
[TBL] [Abstract][Full Text] [Related]
34. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
35. TLR-Stimulated Eosinophils Mediate Recruitment and Activation of NK Cells In Vivo.
O'Flaherty SM; Sutummaporn K; Häggtoft WL; Worrall AP; Rizzo M; Braniste V; Höglund P; Kadri N; Chambers BJ
Scand J Immunol; 2017 Jun; 85(6):417-424. PubMed ID: 28426135
[TBL] [Abstract][Full Text] [Related]
36. IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection.
Kumar P; Rajasekaran K; Nanbakhsh A; Gorski J; Thakar MS; Malarkannan S
Sci Rep; 2019 Mar; 9(1):4984. PubMed ID: 30899058
[TBL] [Abstract][Full Text] [Related]
37. NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis.
Hou X; Zhou R; Wei H; Sun R; Tian Z
Hepatology; 2009 Mar; 49(3):940-9. PubMed ID: 19177594
[TBL] [Abstract][Full Text] [Related]
38. A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
Samara P; Skopeliti M; Tsiatas ML; Georgaki S; Gouloumis C; Voelter W; Dimopoulos AM; Bamias A; Tsitsilonis OE
Anticancer Res; 2016 Jul; 36(7):3373-82. PubMed ID: 27354596
[TBL] [Abstract][Full Text] [Related]
39. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
40. Human hematopoietic CD34+ progenitor cells induce natural killer cell alloresponses via NKG2D activation.
Ulbar F; Nicolini B; Chirumbolo G; Tolomelli G; Steinle A; Rondelli D; Arpinati M
Exp Hematol; 2016 Jan; 44(1):14-23.e1. PubMed ID: 26477527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
